Explanation

Valproate (valproic acid, divalproex) carries significant teratogenic risks that require specific, thorough informed consent for women of reproductive age. The risks include neural tube defects (spina bifida, occurring in 1-2% of exposed pregnancies vs. 0.06% baseline), other congenital malformations (cardiac, craniofacial, limb), and neurodevelopmental effects (decreased IQ scores, increased risk of autism spectrum disorder). The FDA has issued a black box warning and contraindicated valproate for migraine prevention in pregnant women. For a sexually active woman not using contraception, the PMHNP must: discuss these specific risks thoroughly, obtain a pregnancy test before starting the medication, discuss and arrange effective contraception, present alternative mood stabilizers with more favorable reproductive safety profiles (such as lamotrigine), and document the informed consent discussion. Some experts argue that valproate should generally be avoided as a first-line agent in women of reproductive age given available alternatives.

Key Takeaway

Valproate in women of reproductive age requires specific informed consent about teratogenic risk, contraception, and alternatives.